PLUS Therapeutics CFO granted options and RSUs

PLUS THERAPEUTICS, INC. reported that its Chief Financial Officer, Andrew John Hugh MacIntyre, received new equity awards.

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. reported that its Chief Financial Officer, Andrew John Hugh MacIntyre, received new equity awards. He was granted stock options for 3,443 shares of Common Stock at an exercise price of $5.7600 per share, expiring on May 14, 2036. These options vest in substantially equal 1/48th monthly installments over four years and also vest on a change of control as described in his employment agreement.

He also received 3,443 Restricted Stock Units, each representing a right to receive one share of Common Stock. The RSUs vest ratably in 1/12th increments over twelve quarters, starting July 1, 2026, with the remainder vesting quarterly, and his total RSU holdings increased to 30,055 units after this grant.

Insider Trade Summary

Grant/Award: 6,886 shares

Grant/Award 2 txns

Insider Sims Andrew John Hugh MacIntyre

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	3,443	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	3,443	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 30,055 contracts (Direct); Stock Option (Right to Buy) — 3,443 contracts (Direct)

Footnotes (2)

1. F1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.
2. F2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

Key Figures

Stock options granted: 3,443 options Option exercise price: $5.7600 per share Option expiration date: May 14, 2036 +3 more

6 metrics

Stock options granted 3,443 options Grant to CFO on May 14, 2026

Option exercise price $5.7600 per share Stock Option (Right to Buy) grant

Option expiration date May 14, 2036 End of option term

RSUs granted 3,443 RSUs Restricted Stock Units grant to CFO

RSU vesting start July 1, 2026 First 1/12th of RSUs vest

RSUs outstanding after grant 30,055 units Total RSUs held by CFO following transaction

Key Terms

Restricted Stock Unit ("RSU"), vest ratably, change of control, Stock Option (Right to Buy)

4 terms

Restricted Stock Unit ("RSU") financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

vest ratably financial

"The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments"

change of control financial

"and vest on a change of control in accordance with the Optionee's employment agreement"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did PSTV’s CFO report on this Form 4?

PLUS THERAPEUTICS’ CFO reported receiving grants of stock options and Restricted Stock Units. The filing shows 3,443 stock options and 3,443 RSUs awarded as compensation, rather than open-market purchases or sales, increasing his equity-based incentives in the company.

How many stock options did the PSTV CFO receive and at what exercise price?

The CFO received 3,443 stock options, each allowing purchase of one PLUS THERAPEUTICS share at an exercise price of $5.7600. These options are compensation awards and become exercisable gradually over time according to the disclosed vesting schedule.

What are the vesting terms for the PSTV CFO’s new stock options?

The stock options vest over four years in substantially equal 1/48th monthly installments on each monthly anniversary of the grant. They also vest upon a change of control, consistent with the Optionee’s employment agreement, aligning long-term incentives with company performance.

What Restricted Stock Units were granted to PLUS THERAPEUTICS’ CFO?

The CFO received 3,443 Restricted Stock Units, each representing a contingent right to one share of Common Stock. These RSUs are compensation awards that increase his potential share ownership if vesting conditions are satisfied over the stated schedule.

How do the PSTV CFO’s RSUs vest over time after this grant?

The RSUs vest ratably over twelve quarters in approximately equal 1/12th increments. Vesting starts with 1/12th on July 1, 2026, with the remaining portions vesting quarterly thereafter, creating a multi-year incentive horizon tied to continued service.

What is the CFO’s total RSU position in PSTV after the latest grant?

After the latest award, the CFO’s total Restricted Stock Unit holdings are 30,055 units. Each RSU represents a right to receive one share of PLUS THERAPEUTICS Common Stock if the specified vesting conditions and service requirements are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sims Andrew John Hugh MacIntyre

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	05/14/2026		A		3,443		(1)	(1)	Common Stock	3,443	$0	30,055	D
Stock Option (Right to Buy)	$5.76	05/14/2026		A		3,443		(2)	05/14/2036	Common Stock	3,443	$0	3,443	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over twelve quarters in substantially equal 1/12th increments, commencing with 1/12th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.

2. The options vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance and vest on a change of control in accordance with the Optionee's employment agreement.

	Andrew Sims, as attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)